{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:18:55Z","timestamp":1785806335278,"version":"3.56.0"},"reference-count":24,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:00:00Z","timestamp":1553126400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Behav. Cogn. Psychother."],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S1352465819000213_as1\"><jats:title>Background:<\/jats:title><jats:p>Kleptomania is a disease that shares features with obsessive compulsive spectrum disorders (OCD) and with substance abuse disorders (SAD). This is underlined by therapeutic approaches in kleptomania ranging from cognitive behavioural therapy and selective serotonin reuptake inhibitors that are effective in OCD, and opioid antagonists that are currently being used in SAD. However, almost no literature exists about exposure and response prevention (ERP) therapy in kleptomania. Furthermore, there is a clear lack of objective markers that would allow a therapeutic monitoring.<\/jats:p><\/jats:sec><jats:sec id=\"S1352465819000213_as2\"><jats:title>Aim:<\/jats:title><jats:p>To show the effectiveness of ERP therapy in kleptomania in a single case report.<\/jats:p><\/jats:sec><jats:sec id=\"S1352465819000213_as3\"><jats:title>Method:<\/jats:title><jats:p>An ERP therapy under real-world conditions and later augmentation with the opioid antagonist naltrexone is described. Continuous measurements of galvanic skin response (GSR) before, during and after therapy sessions are reported in association with changes of the Kleptomania Symptom Assessment Scale (KSAS) self-questionnaire.<\/jats:p><\/jats:sec><jats:sec id=\"S1352465819000213_as4\"><jats:title>Results:<\/jats:title><jats:p>While KSAS scores showed a clear treatment response to ERP sessions, the GSR was significantly lower during ERP treatment in comparison with baseline measures. However, during augmentation with naltrexone, GSR measures increased again and clinical severity did not further improve.<\/jats:p><\/jats:sec><jats:sec id=\"S1352465819000213_as5\"><jats:title>Conclusions:<\/jats:title><jats:p>This case shows the possible usefulness of ERP-like approaches and therapy monitoring using electrophysiological markers of arousal for individualized treatment in kleptomania.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1352465819000213","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T03:43:49Z","timestamp":1553139829000},"page":"622-627","source":"Crossref","is-referenced-by-count":9,"title":["Exposure and response prevention therapy augmented with naltrexone in kleptomania: a controlled case study using galvanic skin response for monitoring"],"prefix":"10.1017","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5557-4878","authenticated-orcid":false,"given":"Sebastian","family":"Olbrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Stengler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2019,3,21]]},"reference":[{"key":"S1352465819000213_ref1","doi-asserted-by":"publisher","DOI":"10.1177\/070674370605100702"},{"key":"S1352465819000213_ref11","first-page":"175","volume-title":"Clinical Manual of Impulse-Control Disorders","author":"Grant","year":"2006"},{"key":"S1352465819000213_ref4","first-page":"64","article-title":"Naltrexone induced serotonin syndrome","volume":"3","author":"Behnoush","year":"2013","journal-title":"International Journal of Medical Toxicology and Forensic Medicine"},{"key":"S1352465819000213_ref8","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyx015"},{"key":"S1352465819000213_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2014.09.013"},{"key":"S1352465819000213_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2015.05.032"},{"key":"S1352465819000213_ref9","doi-asserted-by":"publisher","DOI":"10.1901\/jaba.1972.5-193"},{"key":"S1352465819000213_ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.0252"},{"key":"S1352465819000213_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2008.11.022"},{"key":"S1352465819000213_ref21","doi-asserted-by":"publisher","DOI":"10.1177\/001316447103100108"},{"key":"S1352465819000213_ref22","doi-asserted-by":"publisher","DOI":"10.3102\/10769986008004289"},{"key":"S1352465819000213_ref14","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000037"},{"key":"S1352465819000213_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2010.03.010"},{"key":"S1352465819000213_ref20","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1067564"},{"key":"S1352465819000213_ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05317-y"},{"key":"S1352465819000213_ref2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1475-1313.2002.00020.x"},{"key":"S1352465819000213_ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.b.32309"},{"key":"S1352465819000213_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cortex.2011.06.021"},{"key":"S1352465819000213_ref12","first-page":"97","article-title":"Symptom severity and its clinical correlates in kleptomania","volume":"30","author":"Grant","year":"2018","journal-title":"Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists"},{"key":"S1352465819000213_ref15","first-page":"3","article-title":"Obsessive-compulsive and spectrum disorders: overview and quality of life issues","volume":"57","author":"Hollander","year":"1996","journal-title":"Journal of Clinical Psychiatry"},{"key":"S1352465819000213_ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2015.12.001"},{"key":"S1352465819000213_ref16","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199901000-00008"},{"key":"S1352465819000213_ref17","doi-asserted-by":"publisher","DOI":"10.1159\/000480539"},{"key":"S1352465819000213_ref23","doi-asserted-by":"publisher","DOI":"10.1159\/000443549"}],"container-title":["Behavioural and Cognitive Psychotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1352465819000213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T23:17:50Z","timestamp":1580426270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1352465819000213\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,21]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1352465819000213"],"URL":"https:\/\/doi.org\/10.1017\/s1352465819000213","relation":{},"ISSN":["1352-4658","1469-1833"],"issn-type":[{"value":"1352-4658","type":"print"},{"value":"1469-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,21]]}}}